Huang Fanke, Dai Qiuting, Zhou Yilu, Guan Jing, Wu Jingjing, Dong Yanyan, Lv Jianfeng
Department of Cardiovascular Medicine, Renhe Hospital Affiliated to Three Gorges University, Yichang, Hubei, China.
Med Sci Monit. 2025 Apr 13;31:e946439. doi: 10.12659/MSM.946439.
Dyslipidemia is a significant risk factor for cardiovascular disease, and managing low-density lipoprotein cholesterol levels is a crucial strategy for both the prevention and treatment of cardiovascular disease. The active ingredient in the novel lipid-lowering drug, inclisiran, is a new type of small interfering RNA that primarily regulates blood lipid levels by inhibiting the synthesis of proprotein convertase subtilisin type 9 (PCSK9). Enhanced lipid-lowering effects can be achieved following 3 administrations. This article summarizes inclisiran's mechanism of action, efficacy, safety, current research hotspots, clinical applications, and future development prospects, based on the latest literature and research advancements. Through comparative analysis with traditional lipid-lowering drugs, we conclude that inclisiran has promising application prospects and market potential, as it can complement traditional statin therapies to enhance lipid-lowering efficiency. This not only provides convenience to patients but also improves treatment compliance. Its safety profile alleviates patients' concerns and mitigates the impact of negative emotions on their condition. Additionally, the potential applications of inclisiran in oncology have been identified. However, inclisiran also presents certain limitations and challenges. For instance, its long-term safety and efficacy require further investigation in future studies, and its high cost can restrict its widespread adoption and promotion. Furthermore, additional clinical evidence is needed to evaluate its synergistic or antagonistic effects when used in conjunction with other medications.
血脂异常是心血管疾病的重要危险因素，控制低密度脂蛋白胆固醇水平是预防和治疗心血管疾病的关键策略。新型降脂药物英克西兰的活性成分是一种新型小干扰RNA，主要通过抑制前蛋白转化酶枯草溶菌素9型（PCSK9）的合成来调节血脂水平。给药3次后可增强降脂效果。本文基于最新文献和研究进展，总结了英克西兰的作用机制、疗效、安全性、当前研究热点、临床应用及未来发展前景。通过与传统降脂药物的对比分析，我们得出结论：英克西兰具有广阔的应用前景和市场潜力，因为它可以补充传统他汀类疗法以提高降脂效率。这不仅为患者提供了便利，还提高了治疗依从性。其安全性减轻了患者的担忧，减轻了负面情绪对病情的影响。此外，还确定了英克西兰在肿瘤学方面的潜在应用。然而，英克西兰也存在一定的局限性和挑战。例如，其长期安全性和疗效需要在未来研究中进一步探讨，其高昂的成本可能会限制其广泛应用和推广。此外，还需要更多临床证据来评估其与其他药物联合使用时的协同或拮抗作用。
